Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

mental > parkinson's disease > Flashcards

parkinson's disease Flashcards

1
Q

what is parkinsonism

A

symptoms similar to PD but have secondary causes

  • drug/toxin - induced
  • vascular (stroke)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

possible causes of PD

A

1) age related loss of neurons
2) environmental toxins/insults

  • MPTP-MPP+
  • pesticides, herbicides

3) genetics

  • predispositions to toxins/insults
  • genetic abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

pathophysiology of PD

A
  • failure to clear abnormal/damaged proteins by ubiquitin/proteasome system -> accumulation of misfolded alpha-synuclein -> formation and accumulation of Lewy body (Aggresomes) inside neurons
  • lewy body mediate functional mitochondria failure -> neuron damage and apoptosis - loss of dopaminergic neurons in substantia nigra
  • long term overexpression of alpha-syn (and neuron apoptosis) -> decrease DA neurotransmission -> motor symptoms
  • neuroinflammation -> activation of microglia -> further neuroinflammation and neurodegeneration -> disease progression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

clinical presentation of PD - 4 characteristics features

A

TRAP

  • tremor: resting tremor that increases w stress, not caused by events
  • rigidity: muscular rigidity, cogwheel rigidity
  • akinesia: slowness of movement, sense of weakness, loss of dexterity, loss of facial expression, reduced blinking
  • postural instability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

PD clinical presentation - initial presentation

A

asymmetric, +ve response to levodopa/apomorphine, sometimes impaired sense of smell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

PD clinical presentation as disease progress

A
  • unable to perform basic ADL
  • choking, pneumonia, falls
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

PD clinical presentation - non motor symptoms

A
  • dementia, depression, psychosis, sleep disorder
  • constipation, GI motility
  • orthostatic hypotension, sialorrhea (drool cuz X swallow)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

PD disease progression timeline

A

20 year prodrome

    • 20 yr: constipation, bladder problem
  • -10 yr: sleep disorder, obesity, depression

20 year disease stage

  • I: unilateral TRA
  • II: bilateral
  • III: poor balance
  • IV: falls, dependency, cognitive decline
  • V: chair/bed bound, dementia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

classifications of PD

A

1) juvenile - onet PD < 20 yo

  • higher freq of genetically inherited PD

2) early/young onset PD < 40 yo

  • slower disease progression
  • lesser cognitive decline
  • earlier motor complication
  • initial presentation: dystonia
  • use dopamine agonist instead of levodopa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

diagnosis of PD

A

1) 2/3 of cardinal signs present (TRAP)
2) neuroimaging

  • MRI for differential diagnosis of other parkinsonism symptoms
  • DAT: differentiate essential tremor and other non-dopamine deficiency aetiologies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

measuring of PD disease progression

A

UPDRS

1) non-motor experience of daily living

  • intellectual impairment, depression

2) motor experiences of daily living

  • speech, salivation, swallowing, dressing, hygiene, walking

3) motor examination

  • facial expression, tremor at rest, gait

4) motor complication

  • dyskinesia, clinical fluctuations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

general approach to PD treatment

A

1) increase central dopamine and dopaminergic transmission

  • inhibit peripheral conversion of levodopa to dopamine by DOPA-decarboxylase, MAO-B and COM-T then inhibit central conversion of dopamine to homovanillic acid by MAO-B and COM-T

2) correct imbalance in other pathways

  • anticholinergics, NMDA antagonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

non pharmaco for PD

A

1) med review

  • correct levodopa preparations (IR vs CR, sinemet 1:10 vs 1:4)
  • DDI, comorb, timing of administration

2) physiotherapy
3) occupational therapy
4) speech therapy
5) deep brain stimulation (DBS) for advanced PD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

types of pharmacological treatment

A

1) levodopa
2) dopamine agonist
3) MAO-B inhibitors
4) catechol-O-methyl transferase inhibitors
5) anticholinergics
6) NMDA antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

indication of levodopa

A

1) try to give others first to minimise motor complications unless cannot be controlled or + other agents so can lower dose of levodopa
2) most effective for treating bradykinesia and rigidity, not so for speech, postural reflex and gait disturbances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

levodopa MOA

A
  • increase dopamine synthesis
  • synthetic L-dopa that is converted into dopamine by DOPA decarboxylase, MAO-B, COM-T
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

DCI (benserazide) for levodopa

A
  • peripheral DOPA-decarboxylase inhibitor to prevent systemic SE from excess DA
  • only L-dopa can cross BBB, dopamine can’t
  • if levodopa converted into dopamine in periphery then can’t cross BBB to take effect
  • so give DCI to ensure levodopa cross BBB then can converted into dopamine to take effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

levodopa formulations

A

1) CR

  • useful for reducing stiffness on waking
  • X rush tablets (sinemet) or open capsule (madopar)

2) dose adjustment required for switching between IR and CR

  • IR -> CR: increase dose by 25 - 50%
  • CR -> IR: reduce dose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

levodopa PK

A
  • absorbed in proximal part of small intestines
  • low F but increased w DCI
  • decreased absorption with high fat/protein meal so need to space apart administration from heavy meals
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

levodopa AE - tldr

A

1) peripheral effects
2) central effects
3) motor effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

levodopa - peripheral effects

A

N/V, orthostatic hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

levodopa - central effects

A

hallucination, psychosis, drowsiness, sudden sleep onset

23
Q

levodopa - motor effects

A

1) “on-off” phenomenon

  • switch between response and no response to levodopa
  • usual unpredictable and unrelated to dose/dosing interval

2) “wearing off”

  • effect of levodopa can wear off before end of dosing interval -> shortened response
  • associated with disease progression
  • management: modify administration time or give CR formulation

3) dyskinesia

  • irreversible
  • usual onset within 3 - 5 years of initiation
  • involuntary, uncontrolled twitching/jerking
  • peak dose dyskinesia and dystonia
  • management
    ** reduce dose if peak dose dyskinesia
    ** replace specific doses w modified release
    ** Add amantadine
24
Q

response to levodopa vs progression

A
  • as disease progress there will be more “off” phases so need to increase dose but might have peak dose dyskinesia
25
Q

levodopa DDI

A

1) pyridoxine

  • cofactor for DOPA-decarboxylase
  • increase decarboxylase activity = decrease levodopa bioavailability
  • technically not a problem if give with DCI but possible interactions if
    ** high B6 for haematological problem
    ** high potency Vit B complex tablets

2) iron, protein (food or powder)

  • affect absorption of levodopa so need to space administration apart

3) dopamine antagonist

  • antiemetic (metoclopramide, prochlorperazine) -> use domperidone instead
  • 1st gen antipsychotics
  • risperidone

4) dopamine agonist

  • additive effects
  • ergot derivatives (bromocriptine)
  • non-ergot derivatives (ropinirole, pramipexole, rotigotine, apomorphine)
26
Q

types of dopamine agonist used

A

ropinirole, pramipexole

27
Q

indication for dopamine agonist

A

1) monotherapy in young onset PD
2) adjunct to levodopa in mod/severe PD
3) management of motor complications in PD

28
Q

MOA of dopamine agonist

A

act on dopamine (d2) receptors in basal ganglia, mimic action of dopamine

29
Q

PK of dopamine agonist

A

1) absorption

  • ergot derivatives lower F than non-ergot derivatives cuz extensive first pass
  • longer t1/2 and duration of action than levodopa

2) ropinirole

  • metabolised by liver -> inactive metabolites
  • titrate w caution for liver impairment

3) pramipexole

  • excreted largely unchanged in urine
  • titrate for renal impairment
30
Q

dopamine agonist AE

A

1) peripheral

  • N/V, orthostatic hypotension, leg oedema

2) central

  • hallucination (visual > auditory)
  • somnolence, day-time sleepiness
  • compulsive behaviour

3) non-dopaminergic

  • fibrosis
    ** pulmonary, pericardiac, retro-peritoneal
    ** partially reversible upon withdrawal
    ** more for ergot derivatives
  • valvular heart disease
    ** more for ergot derivatives
  • management
    ** give apomorphine/rotigotine
31
Q

comparison of dopamine agonist with levodopa

A
  • lesser motor complications
  • more hallucinations, sleep disturbances, leg oedema, orthostatic hypotension
  • no difference in efficacy
  • preferred for younger patients to maximise treatment options and delay onset of levodopa induced motor complications
32
Q

types of MAO-B inhibitors

A

selegiline, rasagiline

33
Q

indication for MAO-B inhibitors

A

monotherapy in early stages esp young onset PD, adjunct in later stages

34
Q

MOA for MAO-B inhibitors

A
  • irreversible
  • inhibit MAO-B from catalysing dopamine to homovanillic acid
35
Q

PK of MAO-B inhibitors

A
  • short t1/2 but long duration of action
  • selegiline hepatically metabolised to amphetamines
    ** stimulating so if BD patient need to take 2nd dose in late afternoon to prevent insomnia
    ** no effect on MAO-B
36
Q

SE of MAO-B inhibtiors

A
  • heartburn, loss of appetite
  • anxiety, palpitation, insomnia
  • nightmare, visual hallucination
37
Q

interactions with MAO-B inhibitors

A

drugs

1) SSRI, SNRI, TCAS (serotonergic syndrome, need washout period)
2) pethidine, tramadol
3) linezolid
4) dextromethorphan
5) dopamine, sympathomimetics, another MAOI

food: tyramine

  • cheese effect
  • sympathomimetic effect -> acute HTN w throbbing headache
  • avoid preserved food and aged food if possible
38
Q

types of catechol-O-methyltransferase inhibitors

A

entacapone

39
Q

indication for entacapone

A
  • only adjunct with levodopa + DCI (must be taken at the same time as levodopa)
  • not effective as monotherapy cuz minimal entry into CNS
  • avoid in hepatic impairment
40
Q

entacapone MOA

A
  • selectively and reversibly inhibit COM-T from catalysing dopamine to homovanillic acid -> more levodopa available to enter brain (need dose reduction of levodopa)
41
Q

entacapone SE

A
  • diarrhoea
  • urine discolouration
  • dyskinesia at initiation (need to lower dose)
  • worsen dopaminergic effect (orthostatic hypotension, N/V)
42
Q

entacapone drug interactions

A

1) Fe, Ca
2) avoid concurrent with non-selective MAOi (can give MAO-B selective, caution for MAO-A)
3) any catecholamine drug
4) enhance anticoagulant effect of warfarin

43
Q

types of anticholinergics

A

trihexyphenidyl

44
Q

anticholinergics general

A
  • only used to control tremor if tremor-predominant symptoms
  • anticholinergics SE
  • peripheral acting agents effective for sialorrhea
45
Q

NMDA antagonist - effects of glutamate

A
  • activation of processes that encourage apoptosis of dopaminergic neurons
  • development and maintenance of levodopa induced dyskinesia
46
Q

types of NMDA antagonist

A

amantadine

47
Q

MOA of NMDA antagonist

A
  • inhibit NMDA receptor from being activated by glutamate
  • anticholinergic
  • upregulate/increase sensitivity of dopamine D2 receptors
  • enhanced release of stored dopamine
48
Q

PK of NMDA antagonist

A
  • renally excreted (reduce dose if renal impairment)
  • can be stimulating (2nd dose given afternoon not night)
49
Q

NMDA antagonist SE

A
  • N/V, lightheaded, insomnia, cognitive impairment, hallucination, nightmare
  • livedo reticularis (venule swelling due to thrombosis -> mottled reticulated discolouration of limbs)
50
Q

alternative medications for PD

A

1) safe but not effective: co-enzyme Q-10, creatine
2) others: Vit E, glutathione, riboflavin, lipoic acid, acetyl carnitine, curcumin

51
Q

general drug induced PD

A
  • bilateral symptoms
  • subacute/acute
  • mostly reversible (withdrawal lead to improvement in 8 wks)
  • variable onset, 3 months within exposure to offending agents
  • more common in elderly cuz polypharmacy
  • can use anticholinergics/amantadine
52
Q

high risk drugs for drug induced PD

A

1) dopamine D2 receptor blockers (FGA, SGA)
2) dopamine depleters (tetrabenazine, reserpine)
3) dopamine synthesis blockers (methyldopa)
4) calcium channel antagonist (flunarizine, cinnarizine)

53
Q

intermediate risk for drug induced PD

A

1) ziprasidone
2) calcium channel antagonist (diltiazem, verapamil)
3) antiepileptics (valproate, phenytoin, levetiracetam)
4) antiemetic and gastric motility agents (prochlorperazine, metoclopramide, substituted benzamines)
5) mood stabiliers (lithium)

mental (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions